$EYEN
EYENOVIA, INC.

2022 Q4 Form 10-Q Financial Statement

#000141057822003306 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $3.170M $3.353M $2.435M
YoY Change -14.59% 37.71% 40.76%
% of Gross Profit
Research & Development $2.282M $3.877M $3.470M
YoY Change -28.15% 11.72% 3.16%
% of Gross Profit
Depreciation & Amortization $78.53K $83.00K $73.01K
YoY Change 7.12% 13.68% 265.05%
% of Gross Profit
Operating Expenses $5.372M $7.230M $5.905M
YoY Change -21.99% 22.44% 15.97%
Operating Profit -$5.372M -$7.230M -$5.905M
YoY Change -272.56% 22.44% 15.97%
Interest Expense -$851.6K $177.1K $119.2K
YoY Change 359.87% 48.59% 2310.76%
% of Operating Profit
Other Income/Expense, Net $100.5K $70.28K -$8.010K
YoY Change 82.12% -977.37%
Pretax Income -$6.123M -$7.309M -$5.569M
YoY Change -305.26% 31.25% 9.19%
Income Tax
% Of Pretax Income
Net Earnings -$6.123M -$7.309M -$5.569M
YoY Change -305.26% 31.25% 9.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21 -$0.21
Diluted Earnings Per Share -$0.17 -$0.21 -$0.21
COMMON SHARES
Basic Shares Outstanding 36.11M 34.21M 26.05M
Diluted Shares Outstanding 34.63M 26.05M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.98M $17.40M $13.50M
YoY Change 18.09% 28.87% -40.94%
Cash & Equivalents $22.90M $17.40M $13.50M
Short-Term Investments $119.6K
Other Short-Term Assets $2.815M $10.59M $8.701M
YoY Change -65.95% 21.69% 275.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.64M $29.42M $23.46M
YoY Change 25.71% 25.4% -7.53%
LONG-TERM ASSETS
Property, Plant & Equipment $1.295M $1.343M $1.413M
YoY Change 1.88% -4.99% 292.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $80.87K $200.2K
YoY Change
Other Assets $726.3K $645.7K $119.0K
YoY Change 42.14% 442.41% -0.8%
Total Long-Term Assets $3.394M $1.988M $1.532M
YoY Change -64.91% 29.77% 219.22%
TOTAL ASSETS
Total Short-Term Assets $27.64M $29.42M $23.46M
Total Long-Term Assets $3.394M $1.988M $1.532M
Total Assets $31.04M $31.41M $24.99M
YoY Change -1.97% 25.66% -3.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.428M $1.105M $1.685M
YoY Change -11.51% -34.41% 15.39%
Accrued Expenses $2.680M $2.564M $1.686M
YoY Change 15.18% 52.06% 56.15%
Deferred Revenue $10.00M
YoY Change
Short-Term Debt $0.00 $7.229M $0.00
YoY Change -100.0%
Long-Term Debt Due $348.9K $7.282M
YoY Change -95.12% 4754.69%
Total Short-Term Liabilities $4.512M $11.02M $20.72M
YoY Change -59.61% -46.83% 207.41%
LONG-TERM LIABILITIES
Long-Term Debt $8.382M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $907.6K $60.54K $26.06K
YoY Change 4449.57% 132.31% -34.85%
Total Long-Term Liabilities $9.290M $60.54K $26.06K
YoY Change 46464.01% 132.31% -94.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.512M $11.02M $20.72M
Total Long-Term Liabilities $9.290M $60.54K $26.06K
Total Liabilities $13.80M $11.08M $20.75M
YoY Change 23.31% -46.61% 188.13%
SHAREHOLDERS EQUITY
Retained Earnings -$118.2M -$112.1M -$93.20M
YoY Change 31.01% 20.28%
Common Stock $3.667K $3.553K $2.597K
YoY Change 28.94% 36.81%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $17.23M $20.33M $4.246M
YoY Change
Total Liabilities & Shareholders Equity $31.04M $31.41M $24.99M
YoY Change -1.97% 25.66% -3.32%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$6.123M -$7.309M -$5.569M
YoY Change -305.26% 31.25% 9.26%
Depreciation, Depletion And Amortization $78.53K $83.00K $73.01K
YoY Change 7.12% 13.68% 265.05%
Cash From Operating Activities -$5.405M -$6.817M -$5.095M
YoY Change -8.03% 33.81% 163.97%
INVESTING ACTIVITIES
Capital Expenditures $30.99K -$228.0K -$517.3K
YoY Change -150.38% -55.92% 639.04%
Acquisitions
YoY Change
Other Investing Activities -$280.8K $64.71K
YoY Change -28.36%
Cash From Investing Activities -$311.8K -$163.3K -$517.3K
YoY Change -31.24% -68.43% 639.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $8.025M
YoY Change
Cash From Financing Activities 3.307M 2.872M -189.0K
YoY Change -73.1% -1619.93% -101.29%
NET CHANGE
Cash From Operating Activities -5.405M -6.817M -5.095M
Cash From Investing Activities -311.8K -163.3K -517.3K
Cash From Financing Activities 3.307M 2.872M -189.0K
Net Change In Cash -2.410M -4.108M -5.801M
YoY Change -140.43% -29.18% -145.71%
FREE CASH FLOW
Cash From Operating Activities -$5.405M -$6.817M -$5.095M
Capital Expenditures $30.99K -$228.0K -$517.3K
Free Cash Flow -$5.436M -$6.589M -$4.577M
YoY Change -6.52% 43.95% 146.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34631774
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26053532
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32778551
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25773098
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001682639
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35525689
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28426616
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38365
dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
393-6684
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
dei Trading Symbol
TradingSymbol
EYEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36112987
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17398605
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19461850
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
7875000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7875000
CY2022Q3 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
1871096
CY2022Q3 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
809430
CY2021Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
1805065
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1463020
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
721438
CY2022Q3 us-gaap Assets Current
AssetsCurrent
29417151
CY2021Q4 us-gaap Assets Current
AssetsCurrent
29863353
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1342657
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1271225
CY2022Q3 eyen Security Deposits
SecurityDeposits
200153
CY2021Q4 eyen Security Deposits
SecurityDeposits
132539
CY2022Q3 eyen Equipment Deposits
EquipmentDeposits
445530
CY2021Q4 eyen Equipment Deposits
EquipmentDeposits
391941
CY2022Q3 us-gaap Assets
Assets
31405491
CY2021Q4 us-gaap Assets
Assets
31659058
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1104959
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1614104
CY2022Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1268009
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1543618
CY2022Q3 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
1384803
CY2021Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
845719
CY2022Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
28999
CY2021Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
18685
CY2022Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7229013
CY2021Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7150368
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11015783
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11172494
CY2022Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
60540
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
19949
CY2022Q3 us-gaap Liabilities
Liabilities
11076323
CY2021Q4 us-gaap Liabilities
Liabilities
11192443
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35525689
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28426616
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3553
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2844
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132432682
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
110683077
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112107067
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90219306
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20329168
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20466615
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31405491
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31659058
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
0
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
0
us-gaap Cost Of Revenue
CostOfRevenue
0
us-gaap Cost Of Revenue
CostOfRevenue
1600000
CY2022Q3 us-gaap Gross Profit
GrossProfit
0
CY2021Q3 us-gaap Gross Profit
GrossProfit
0
us-gaap Gross Profit
GrossProfit
0
us-gaap Gross Profit
GrossProfit
2400000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3876876
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3552068
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11176326
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11559364
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3353352
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2372999
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10362907
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6914481
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7230228
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5925067
us-gaap Operating Expenses
OperatingExpenses
21539233
us-gaap Operating Expenses
OperatingExpenses
18473845
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7230228
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5925067
us-gaap Operating Income Loss
OperatingIncomeLoss
-21539233
us-gaap Operating Income Loss
OperatingIncomeLoss
-16073845
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
463353
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
463353
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70277
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11728
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96580
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
48880
CY2022Q3 us-gaap Interest Expense
InterestExpense
177138
CY2021Q3 us-gaap Interest Expense
InterestExpense
119212
us-gaap Interest Expense
InterestExpense
475811
us-gaap Interest Expense
InterestExpense
202407
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
28093
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
600
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
30703
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2354
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7308996
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5568598
us-gaap Net Income Loss
NetIncomeLoss
-21887761
us-gaap Net Income Loss
NetIncomeLoss
-15761665
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4841400
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34631774
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26053532
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32778551
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25773098
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20466615
CY2022Q1 eyen Stock Issued During Period Value New Issues One
StockIssuedDuringPeriodValueNewIssuesOne
14897908
CY2022Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
860365
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908987
CY2022Q1 eyen Restricted Stock Issued During Period Value New Issues
RestrictedStockIssuedDuringPeriodValueNewIssues
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794210
CY2022Q2 eyen Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18701
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036926
CY2022Q2 eyen Restricted Stock Issued During Period Value New Issues
RestrictedStockIssuedDuringPeriodValueNewIssues
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7239100
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23610737
CY2022Q3 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3098694
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
928733
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7308996
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
20329168
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15303885
CY2021Q1 eyen Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1530990
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
656913
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5351667
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
12140121
CY2021Q2 eyen Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
573001
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130090
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
351390
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
637355
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
8990557
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46712
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
777467
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5568598
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4246138
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
354539
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3149
us-gaap Net Income Loss
NetIncomeLoss
-21887761
us-gaap Net Income Loss
NetIncomeLoss
-15761665
us-gaap Share Based Compensation
ShareBasedCompensation
2874646
us-gaap Share Based Compensation
ShareBasedCompensation
2071735
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
228898
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148245
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
78645
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
41944
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
209040
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
463353
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
66250
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35549
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-995635
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-2005859
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1871096
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
0
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-1600000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-67614
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-509145
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
223068
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-275609
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33564
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
539084
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-928356
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4000000
eyen Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
50905
eyen Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-4397
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19700622
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14997807
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
509370
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1165066
eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
53589
eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-562959
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1165066
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
14981299
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
0
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
3959059
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18701
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2103991
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7500000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
675332
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
547259
eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
83391
eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
66618
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
176802
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18200336
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9166916
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2063245
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6995957
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27336850
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28371828
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25273605
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21375871
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17398605
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13500871
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7875000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7875000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25273605
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21375871
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
315550
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
131839
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
675332
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
705360
eyen Issuance Of Stock Warrants
IssuanceOfStockWarrants
351390
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
9
eyen Percentage Of Success Rate Of Optejet
PercentageOfSuccessRateOfOptejet
0.98
eyen Percentage Of Successful Rate Of Traditional Eye Drops
PercentageOfSuccessfulRateOfTraditionalEyeDrops
0.50
eyen Technology Provides Reduction In Ocular Drug And Preservative Exposure Percent
TechnologyProvidesReductionInOcularDrugAndPreservativeExposurePercent
0.75
eyen Percent Eyedrops Expose Ocular Surface
PercentEyedropsExposeOcularSurface
3
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17400000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112100000
us-gaap Net Income Loss
NetIncomeLoss
-21900000
us-gaap Net Income Loss
NetIncomeLoss
-15800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15000000.0
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
7875000
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
24773605
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
26836850
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11745332
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5611839
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</p>
CY2022Q3 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
621063
CY2021Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
343785
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
455150
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
171370
CY2022Q3 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
185845
CY2021Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
71375
CY2022Q3 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
100803
CY2021Q4 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
12586
CY2022Q3 eyen Prepaid Patent Expense
PrepaidPatentExpense
49183
CY2021Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
32797
CY2022Q3 us-gaap Other Assets
OtherAssets
32226
CY2021Q4 us-gaap Other Assets
OtherAssets
4525
CY2022Q3 eyen Prepaid Security Deposits
PrepaidSecurityDeposits
18750
CY2021Q4 eyen Prepaid Security Deposits
PrepaidSecurityDeposits
18750
CY2022Q3 eyen Prepaid Director Fees Current
PrepaidDirectorFeesCurrent
0
CY2021Q4 eyen Prepaid Director Fees Current
PrepaidDirectorFeesCurrent
66250
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1463020
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
721438
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
971159
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1245795
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
296850
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
297823
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1268009
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1543618
CY2022Q3 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
711710
CY2021Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
436840
CY2022Q3 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
386712
CY2021Q4 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
250000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
152969
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
94792
CY2022Q3 eyen Credit Card Payable
CreditCardPayable
58799
CY2021Q4 eyen Credit Card Payable
CreditCardPayable
20000
CY2022Q3 eyen Accrued Franchise Tax
AccruedFranchiseTax
39300
CY2021Q4 eyen Accrued Franchise Tax
AccruedFranchiseTax
1680
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29647
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
42407
CY2022Q3 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
5666
CY2021Q4 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
0
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1384803
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
845719
CY2022Q1 us-gaap Supplemental Unemployment Benefits Salary Continuation
SupplementalUnemploymentBenefitsSalaryContinuation
1517000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
928733
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
777467
us-gaap Share Based Compensation
ShareBasedCompensation
2874646
us-gaap Share Based Compensation
ShareBasedCompensation
2071735
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
41778
CY2021Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
3.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
193304
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
1.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
55319
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
3.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
6963
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeited In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice
3.59
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
172800
CY2022Q3 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
1.80
eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
41086
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
3.64
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P4Y6M
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5484687
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y6M
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3518147
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4058569
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1217715
CY2021Q4 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.69
eyen Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
6740260
eyen Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
2.56
eyen Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1870130
eyen Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.01
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6087845
CY2022Q3 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
3.37
eyen Class Of Warrant Or Right Outstanding Weighted Average Remaining Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife
P4Y6M
CY2022Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
6087845
CY2022Q3 eyen Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
3.37
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P4Y6M
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6087845
CY2022Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
6087845
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1870130
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
18701
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2022Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
39914
CY2021Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
34076
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
173896
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
144917

Files In Submission

Name View Source Status
0001410578-22-003306-index-headers.html Edgar Link pending
0001410578-22-003306-index.html Edgar Link pending
0001410578-22-003306.txt Edgar Link pending
0001410578-22-003306-xbrl.zip Edgar Link pending
eyen-20220930.xsd Edgar Link pending
eyen-20220930x10q.htm Edgar Link pending
eyen-20220930xex10d1.htm Edgar Link pending
eyen-20220930xex31d1.htm Edgar Link pending
eyen-20220930xex31d2.htm Edgar Link pending
eyen-20220930xex32d1.htm Edgar Link pending
eyen-20220930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
eyen-20220930_pre.xml Edgar Link unprocessable
eyen-20220930_lab.xml Edgar Link unprocessable
eyen-20220930_def.xml Edgar Link unprocessable
eyen-20220930x10q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eyen-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable